Supplementary Protection Certificate (SPC) Summary | |||
SPC No. | 2017/035 | ||
---|---|---|---|
Date of filing | 15/08/2017 | ||
Notification of Application Published | 06/09/2017 | ||
Status | Rejected | ||
Notification of Grant Published | |||
Date of Expiry of SPC | |||
Applicant |
GEORGETOWN UNIVERSITY 37th and O Streets, N.W. Washington, DC 20057 UNITED STATES OF AMERICA |
||
Patent Number | 1776957 | ||
Title of Invention | USE OF HERPES VECTORS FOR TUMOR THERAPY | ||
Date of Expiry of Patent | 11/08/2018 | ||
Product Type | Medicinal Product | ||
Product Identity | Talimogene laherparepvec | ||
Market Authorisation | Ireland | ||
Authorisation No | EU/1/15/1064/001 and EU/1/15/1064/002 | ||
Authorisation Date | 16/12/2015 | ||
Identity of Product Authorised | Imlygic-talimogene laherparepvec | ||
Address for Service |
Anne Ryan & Co 2 Crofton Terrace Dun Laoghaire Co. Dublin A96 V6P7 IRELAND |
||
Renewal Fees | |||
17/08/2017 | Request for grant a Supplementary Protection Certificate filed on 15/08/2017, numbered 2017/035. | ||
05/05/2021 | Request for grant of Supplementary Protection Certification No. 2017/035 rejected in respect of Article 10(2) of Regulation (EC) No. 469/2009 | ||
19/05/2021 | Written statement of grounds issued on 19 May 2021. | ||
20/10/2021 | Appeal against decision of the Controller filed in the High Court on 18 August 2021 [Record No. 2021/144Sp] | ||
20/10/2021 | Notice of discontinuance of appeal against decision of the Controller filed on 14 October 2021 [2021 No. 144 Sp] |